Header Logo

Connection

DAVID GRAHAM to Anti-Bacterial Agents

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Anti-Bacterial Agents.
DAVID GRAHAM
Connection Strength
16.590
Anti-Bacterial Agents
  1. Overcoming the effects of increasing antimicrobial resistance on Helicobacter pylori therapy. Expert Rev Gastroenterol Hepatol. 2024 Nov; 18(11):705-711.
    View in: PubMed
    Score: 0.417
  2. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2025 Apr 01; 120(4):787-798.
    View in: PubMed
    Score: 0.410
  3. Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data. Helicobacter. 2024 Jul-Aug; 29(4):e13112.
    View in: PubMed
    Score: 0.404
  4. Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies. Gastroenterology. 2021 11; 161(5):1433-1442.e2.
    View in: PubMed
    Score: 0.329
  5. National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial. Gastroenterology. 2021 07; 161(1):342-344.e1.
    View in: PubMed
    Score: 0.323
  6. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.317
  7. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Rev Gastroenterol Hepatol. 2019 Jan; 13(1):17-24.
    View in: PubMed
    Score: 0.274
  8. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018 07; 155(1):67-75.
    View in: PubMed
    Score: 0.261
  9. Brief report: Lactobacillus bulgaricus GLB44 (Proviotic? ) plus esomeprazole for Helicobacter pylori eradication: A pilot study. Helicobacter. 2018 Apr; 23(2):e12476.
    View in: PubMed
    Score: 0.261
  10. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017 12; 66(12):2043-2046.
    View in: PubMed
    Score: 0.253
  11. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017 07; 14(7):383-384.
    View in: PubMed
    Score: 0.246
  12. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017 Apr; 84(4):310-318.
    View in: PubMed
    Score: 0.245
  13. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci. 2016 11; 61(11):3215-3220.
    View in: PubMed
    Score: 0.236
  14. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May; 65(5):870-8.
    View in: PubMed
    Score: 0.226
  15. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 05; 150(5):1113-1124.e5.
    View in: PubMed
    Score: 0.226
  16. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015 Dec 07; 21(45):12954-62.
    View in: PubMed
    Score: 0.223
  17. Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype. Helicobacter. 2016 Apr; 21(2):85-90.
    View in: PubMed
    Score: 0.223
  18. Letter: clarithromycin dose for H.?pylori therapy remains unresolved. Aliment Pharmacol Ther. 2015 Sep; 42(5):631-2.
    View in: PubMed
    Score: 0.219
  19. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
    View in: PubMed
    Score: 0.216
  20. Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance. Aliment Pharmacol Ther. 2015 Jun; 41(11):1220-1.
    View in: PubMed
    Score: 0.215
  21. Roadmap for elimination of gastric cancer in Korea. Korean J Intern Med. 2015 Mar; 30(2):133-9.
    View in: PubMed
    Score: 0.212
  22. RE: Effects of helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014 Nov; 106(11).
    View in: PubMed
    Score: 0.207
  23. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol. 2014 Sep 07; 20(33):11552-9.
    View in: PubMed
    Score: 0.205
  24. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014 Aug; 19(4):319-22.
    View in: PubMed
    Score: 0.199
  25. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des. 2014; 20(28):4510-6.
    View in: PubMed
    Score: 0.195
  26. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014 Jan; 8(1):21-8.
    View in: PubMed
    Score: 0.194
  27. Helicobacter pylori eradication and metachronous gastric cancer. Clin Gastroenterol Hepatol. 2014 May; 12(5):801-3.
    View in: PubMed
    Score: 0.193
  28. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct; 25(10):1134-40.
    View in: PubMed
    Score: 0.192
  29. Helicobacter pylori: tailored therapy with novel sequential quadruple therapies. Nat Rev Gastroenterol Hepatol. 2013 Jan; 10(1):6-8.
    View in: PubMed
    Score: 0.181
  30. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012 Oct; 17(5):382-90.
    View in: PubMed
    Score: 0.175
  31. Which Therapy for Helicobacter pylori Infection? Gastroenterology. 2012 Jul; 143(1):10-2.
    View in: PubMed
    Score: 0.174
  32. Guide regarding choice of second-line therapy to obtain a high cumulative cure rate. Helicobacter. 2012 Aug; 17(4):243-5.
    View in: PubMed
    Score: 0.173
  33. Treatment of Helicobacter pylori in Latin America. Lancet. 2012 Feb 04; 379(9814):408; author reply 408-9.
    View in: PubMed
    Score: 0.171
  34. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol. 2012 Jan; 27(1):59-61.
    View in: PubMed
    Score: 0.170
  35. Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. J Dig Dis. 2012 Jan; 13(1):54-9.
    View in: PubMed
    Score: 0.170
  36. Helicobacter pylori therapy demystified. Helicobacter. 2011 Oct; 16(5):343-5.
    View in: PubMed
    Score: 0.167
  37. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr; 45(4):309-13.
    View in: PubMed
    Score: 0.161
  38. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr; 16(2):139-45.
    View in: PubMed
    Score: 0.161
  39. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr; 16(2):146-52.
    View in: PubMed
    Score: 0.161
  40. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010 Sep; 39(3):465-80.
    View in: PubMed
    Score: 0.155
  41. Helicobacter pylori infection in India from a western perspective. Indian J Med Sci. 2010 Sep; 64(9):423-40.
    View in: PubMed
    Score: 0.155
  42. Helicobacter pylori infection. N Engl J Med. 2010 08 05; 363(6):595-6; author reply 596.
    View in: PubMed
    Score: 0.154
  43. Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol. 2010 Dec; 8(12):1032-6.
    View in: PubMed
    Score: 0.154
  44. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug; 59(8):1143-53.
    View in: PubMed
    Score: 0.152
  45. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010 Aug; 45(8):816-20.
    View in: PubMed
    Score: 0.150
  46. OLGA can guard the barn. Am J Gastroenterol. 2009 Dec; 104(12):3099; author reply 3101-2.
    View in: PubMed
    Score: 0.147
  47. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):36-41.e1.
    View in: PubMed
    Score: 0.145
  48. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun; 5(6):321-31.
    View in: PubMed
    Score: 0.132
  49. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
    View in: PubMed
    Score: 0.129
  50. Ethical considerations of comparing sequential and traditional anti Helicobacter pylori therapy. Ann Intern Med. 2007 Sep 18; 147(6):434-5.
    View in: PubMed
    Score: 0.126
  51. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007 Aug; 12(4):275-8.
    View in: PubMed
    Score: 0.125
  52. One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut. 2007 Jul; 56(7):1021-3; author reply 1022-3.
    View in: PubMed
    Score: 0.124
  53. Natural history of gastric cancer after Helicobacter pylori eradication in Japan: after endoscopic resection, after treatment of the general population, and naturally. Helicobacter. 2006 Jun; 11(3):139-43.
    View in: PubMed
    Score: 0.115
  54. Is there a role for sequential in sequential anti-H. pylori therapy? Gastroenterology. 2006 May; 130(6):1930-1; author reply 1931.
    View in: PubMed
    Score: 0.115
  55. Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
    View in: PubMed
    Score: 0.104
  56. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther. 2004 Aug; 2(4):599-610.
    View in: PubMed
    Score: 0.102
  57. Toward Quantification of H pylori-associated Gastric Cancer Risk: Further Evidence Supporting Development of Population-based Strategies for H pylori Eradication. Gastroenterology. 2024 02; 166(2):248-249.
    View in: PubMed
    Score: 0.096
  58. The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology. 2003 Aug; 125(2):639; author reply 640-1.
    View in: PubMed
    Score: 0.095
  59. It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials. Am J Gastroenterol. 2023 07 01; 118(7):1154-1156.
    View in: PubMed
    Score: 0.093
  60. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
    View in: PubMed
    Score: 0.092
  61. Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
    View in: PubMed
    Score: 0.092
  62. How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert Rev Gastroenterol Hepatol. 2023 Jan; 17(1):1-7.
    View in: PubMed
    Score: 0.091
  63. Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis. Helicobacter. 2023 Feb; 28(1):e12936.
    View in: PubMed
    Score: 0.091
  64. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. Am J Gastroenterol. 2022 04 01; 117(4):524-528.
    View in: PubMed
    Score: 0.086
  65. Comparable Results of Helicobacter pylori Antibiotic Resistance Testing of Stools vs Gastric Biopsies Using Next-Generation Sequencing. Gastroenterology. 2022 06; 162(7):2095-2097.e2.
    View in: PubMed
    Score: 0.086
  66. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022 01 27; 73:183-195.
    View in: PubMed
    Score: 0.085
  67. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut. 2022 03; 71(3):643-650.
    View in: PubMed
    Score: 0.084
  68. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001 May 14; 161(9):1217-20.
    View in: PubMed
    Score: 0.081
  69. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021 08; 161(2):495-507.e4.
    View in: PubMed
    Score: 0.081
  70. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance. Aliment Pharmacol Ther. 2001 Apr; 15(4):513-8.
    View in: PubMed
    Score: 0.081
  71. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol. 2022 05; 20(5):973-983.e1.
    View in: PubMed
    Score: 0.081
  72. Environmental antimicrobial resistance is associated with faecal pollution in Central Thailand's coastal aquaculture region. J Hazard Mater. 2021 08 15; 416:125718.
    View in: PubMed
    Score: 0.081
  73. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter. 2021 Jun; 26(3):e12801.
    View in: PubMed
    Score: 0.080
  74. Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter. 2021 Feb; 26(1):e12773.
    View in: PubMed
    Score: 0.079
  75. European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut. 2021 01; 70(1):1-2.
    View in: PubMed
    Score: 0.078
  76. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother. 2000 Aug; 44(8):2133-42.
    View in: PubMed
    Score: 0.077
  77. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
    View in: PubMed
    Score: 0.076
  78. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020 06 16; 172(12):795-802.
    View in: PubMed
    Score: 0.076
  79. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug; 25(4):e12692.
    View in: PubMed
    Score: 0.076
  80. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother. 2000 Mar; 1(3):507-14.
    View in: PubMed
    Score: 0.075
  81. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci. 2000 Jan; 45(1):68-76.
    View in: PubMed
    Score: 0.074
  82. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera? or Lactobacillus reuteri for treatment na?ve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019 Dec; 24(6):e12659.
    View in: PubMed
    Score: 0.072
  83. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents. 1999 Aug; 12(4):341-7.
    View in: PubMed
    Score: 0.072
  84. Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply. Aliment Pharmacol Ther. 2019 08; 50(3):332.
    View in: PubMed
    Score: 0.072
  85. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999 Jun; 4(2):106-12.
    View in: PubMed
    Score: 0.071
  86. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019 Aug; 24(4):e12596.
    View in: PubMed
    Score: 0.071
  87. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 06; 49(11):1385-1394.
    View in: PubMed
    Score: 0.071
  88. Diagnosis and management of Helicobacter pylori infection. Clin Cornerstone. 1999; 1(5):18-28.
    View in: PubMed
    Score: 0.069
  89. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol. 2019; 1149:211-225.
    View in: PubMed
    Score: 0.069
  90. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis. 2018 Nov; 19(11):674-677.
    View in: PubMed
    Score: 0.068
  91. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018 09; 16(9):679-687.
    View in: PubMed
    Score: 0.067
  92. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2018 09; 16(9):1427-1433.
    View in: PubMed
    Score: 0.065
  93. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. Dig Dis Sci. 1998 Mar; 43(3):464-7.
    View in: PubMed
    Score: 0.065
  94. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology. 2018 Feb; 154(3):462-466.
    View in: PubMed
    Score: 0.065
  95. Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol. 2018 09; 16(9):1531-1532.
    View in: PubMed
    Score: 0.064
  96. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.064
  97. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Oct; 11(5):935-8.
    View in: PubMed
    Score: 0.063
  98. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother. 1997 Aug; 40(2):283-6.
    View in: PubMed
    Score: 0.063
  99. Update on Helicobacter pylori research. Eradication. Eur J Gastroenterol Hepatol. 1997 Jun; 9(6):626-8.
    View in: PubMed
    Score: 0.062
  100. It is time to rethink H. pylori therapy. J Gastrointestin Liver Dis. 2017 06; 26(2):115-117.
    View in: PubMed
    Score: 0.062
  101. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 01; 66(1):6-30.
    View in: PubMed
    Score: 0.059
  102. One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1996 Aug; 10(4):617-21.
    View in: PubMed
    Score: 0.058
  103. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogot?-Colombia (2009-2014). PLoS One. 2016; 11(7):e0160007.
    View in: PubMed
    Score: 0.058
  104. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut. 2017 02; 66(2):384-386.
    View in: PubMed
    Score: 0.057
  105. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther. 1996 Feb; 10(1):119-22.
    View in: PubMed
    Score: 0.056
  106. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis. 1996 Jan; 24(1):37-41.
    View in: PubMed
    Score: 0.056
  107. Mycobacterium paratuberculosis as a cause of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2015; 9(12):1523-34.
    View in: PubMed
    Score: 0.055
  108. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015 Nov; 64(11):1715-20.
    View in: PubMed
    Score: 0.055
  109. Helicobacter pylori: New Thoughts and Practices. Gastroenterol Clin North Am. 2015 Sep; 44(3):xv-xvi.
    View in: PubMed
    Score: 0.054
  110. Editorial: quadruple therapy for H. pylori eradication is better than triple therapy - authors' reply. Aliment Pharmacol Ther. 2015 Apr; 41(7):695-6.
    View in: PubMed
    Score: 0.053
  111. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015 Sep; 13(9):1616-24.
    View in: PubMed
    Score: 0.053
  112. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015 Apr; 148(4):719-31.e3.
    View in: PubMed
    Score: 0.053
  113. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagn Microbiol Infect Dis. 2015 Apr; 81(4):251-5.
    View in: PubMed
    Score: 0.052
  114. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014 Jun; 19(3):207-13.
    View in: PubMed
    Score: 0.049
  115. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):177-86.e3; Discussion e12-3.
    View in: PubMed
    Score: 0.047
  116. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013 Oct; 18(5):373-7.
    View in: PubMed
    Score: 0.046
  117. Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):319-25.
    View in: PubMed
    Score: 0.040
  118. Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):326-32.
    View in: PubMed
    Score: 0.040
  119. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011 Jun 14; 183(9):E506-8.
    View in: PubMed
    Score: 0.040
  120. Addition of gentamicin to endoscopic retrograde cholangiopancreatography (ERCP) contrast medium towards reducing the frequency of septic complications of ERCP. J Dig Dis. 2010 Aug; 11(4):237-43.
    View in: PubMed
    Score: 0.039
  121. Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol. 2010 Mar; 44(3):167-72.
    View in: PubMed
    Score: 0.037
  122. CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology. 2010 May; 138(5):1836-44.
    View in: PubMed
    Score: 0.037
  123. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009 Apr; 14(2):109-18.
    View in: PubMed
    Score: 0.035
  124. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):145-8.
    View in: PubMed
    Score: 0.034
  125. Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes. Dig Dis Sci. 2008 Sep; 53(9):2541-9.
    View in: PubMed
    Score: 0.033
  126. Ulcers and gastritis. Endoscopy. 2008 Feb; 40(2):136-9.
    View in: PubMed
    Score: 0.032
  127. Helicobacter pylori eradication and its effect on iron stores: a reappraisal. J Infect Dis. 2006 Sep 01; 194(5):714; author reply 715-6.
    View in: PubMed
    Score: 0.029
  128. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am. 2006 Jun; 35(2):229-47.
    View in: PubMed
    Score: 0.029
  129. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther. 2006 Jan 15; 23(2):295-301.
    View in: PubMed
    Score: 0.028
  130. Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004 Sep; 53(9):1235-43.
    View in: PubMed
    Score: 0.026
  131. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.025
  132. A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter. 2024 Jan-Feb; 29(1):e13061.
    View in: PubMed
    Score: 0.024
  133. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003 Dec; 8(6):626-42.
    View in: PubMed
    Score: 0.024
  134. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
    View in: PubMed
    Score: 0.024
  135. Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method. Gut. 2023 11 24; 72(12):2231-2240.
    View in: PubMed
    Score: 0.024
  136. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023 Dec; 28(6):e13019.
    View in: PubMed
    Score: 0.024
  137. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003 Aug; 8(4):307-9.
    View in: PubMed
    Score: 0.024
  138. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.023
  139. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022; 13:1049908.
    View in: PubMed
    Score: 0.023
  140. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 02 01; 118(2):269-275.
    View in: PubMed
    Score: 0.022
  141. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 12; 69(12):2093-2112.
    View in: PubMed
    Score: 0.019
  142. Helicobacter pylori. Med Clin North Am. 2000 Sep; 84(5):1125-36, viii.
    View in: PubMed
    Score: 0.019
  143. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021 02; 70(2):243-250.
    View in: PubMed
    Score: 0.019
  144. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000 Aug; 44(8):2214-6.
    View in: PubMed
    Score: 0.019
  145. Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol Lett. 2000 Jul 15; 188(2):197-202.
    View in: PubMed
    Score: 0.019
  146. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci. 2020 12; 65(12):3639-3646.
    View in: PubMed
    Score: 0.019
  147. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95.
    View in: PubMed
    Score: 0.018
  148. Editorial: recurrence of Helicobacter pylori infection-still the same after all these years? Authors' reply. Aliment Pharmacol Ther. 2018 01; 47(1):132-133.
    View in: PubMed
    Score: 0.016
  149. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997 Nov; 108(5):504-9.
    View in: PubMed
    Score: 0.016
  150. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. Aliment Pharmacol Ther. 1997 Oct; 11(5):939-42.
    View in: PubMed
    Score: 0.016
  151. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Jun; 11(3):529-32.
    View in: PubMed
    Score: 0.015
  152. Decrease in gastric permeability to sucrose following cure of Helicobacter pylori infection. Helicobacter. 1997 Mar; 2(1):44-7.
    View in: PubMed
    Score: 0.015
  153. Twenty-minute fasting version of the US 13C-urea breath test for the diagnosis of H. pylori infection. Helicobacter. 1996 Sep; 1(3):165-7.
    View in: PubMed
    Score: 0.015
  154. Resolution of a metaplastic duodenal polyp after cure of Helicobacter pylori infection. J Clin Gastroenterol. 1996 Jul; 23(1):53-4.
    View in: PubMed
    Score: 0.015
  155. Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol. 1996 Apr; 91(4):690-4.
    View in: PubMed
    Score: 0.014
  156. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep; 64(9):1353-67.
    View in: PubMed
    Score: 0.014
  157. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. World J Gastroenterol. 2014 Mar 28; 20(12):3343-9.
    View in: PubMed
    Score: 0.012
  158. Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogot? D.C., Colombia. J Microbiol. 2013 Aug; 51(4):448-52.
    View in: PubMed
    Score: 0.012
  159. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013 08; 10(8):495-500.
    View in: PubMed
    Score: 0.012
  160. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol. 1993 Jun; 24(6):577-83.
    View in: PubMed
    Score: 0.012
  161. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol. 2012 May-Jun; 46(5):397-400.
    View in: PubMed
    Score: 0.011
  162. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May; 61(5):646-64.
    View in: PubMed
    Score: 0.011
  163. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol. 1989 Mar; 84(3):233-8.
    View in: PubMed
    Score: 0.009
  164. Clinical impact of stool cultures for Campylobacter in adults with acute or chronic diarrhea. South Med J. 1987 Jun; 80(6):709-11.
    View in: PubMed
    Score: 0.008
  165. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun; 56(6):772-81.
    View in: PubMed
    Score: 0.007
  166. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002 Apr; 97(4):857-60.
    View in: PubMed
    Score: 0.005
  167. Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria. Dig Dis Sci. 2000 Mar; 45(3):445-56.
    View in: PubMed
    Score: 0.005
  168. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother. 1999 Jan; 43(1):47-54.
    View in: PubMed
    Score: 0.004
  169. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis. 1998 Jul; 27(1):84-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.